WallStSmart

Medtronic PLC (MDT)vsRapid Micro Biosystems Inc (RPID)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 105548% more annual revenue ($35.48B vs $33.59M). MDT leads profitability with a 13.0% profit margin vs -140.3%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

RPID

Avoid

33

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -5.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for RPID.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

RPID1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37.3%10/10

Revenue surging 37.3% year-over-year

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

RPID4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$104.56M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-86.8%2/10

ROE of -86.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : RPID

The strongest argument for RPID centers on Revenue Growth. Revenue growth of 37.3% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : RPID

The primary concerns for RPID are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

MDT profiles as a value stock while RPID is a hypergrowth play — different risk/reward profiles.

RPID carries more volatility with a beta of 1.39 — expect wider price swings.

RPID is growing revenue faster at 37.3% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Rapid Micro Biosystems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rapid Micro Biosystems Inc is an innovative biotechnology company focused on revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated growth-based microbial detection technologies, the firm significantly improves the precision and efficiency of microbial testing, ensuring high product quality and regulatory compliance. With an increasing demand for rapid, reliable quality control solutions in regulated environments, Rapid Micro is well-positioned to meet these urgent market needs and lead the evolution of microbiological testing methodologies.

Visit Website →

Want to dig deeper into these stocks?